Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) - Zacks Research boosted their FY2026 earnings per share (EPS) estimates for Bio-Rad Laboratories in a report released on Tuesday, August 25th. Zacks Research analyst Team now forecasts that the medical research company will earn $9.71 per share for the year, up from their previous forecast of $9.42. Zacks Research currently has a "Hold" rating on the stock. The consensus estimate for Bio-Rad Laboratories' current full-year earnings is $9.14 per share. Zacks Research also issued estimates for Bio-Rad Laboratories' Q2 2027 earnings at $2.23 EPS, Q3 2027 earnings at $2.25 EPS, Q4 2027 earnings at $2.32 EPS, FY2027 earnings at $9.02 EPS, Q2 2028 earnings at $2.32 EPS and FY2028 earnings at $9.26 EPS.
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $1.75 by $0.87. The firm had revenue of $651.00 million during the quarter, compared to the consensus estimate of $623.99 million. Bio-Rad Laboratories had a return on equity of 3.54% and a net margin of 8.59%.The company's revenue for the quarter was down .1% on a year-over-year basis. During the same period last year, the company earned $2.61 earnings per share.
Several other analysts have also recently commented on the stock. Wells Fargo & Company raised their target price on shares of Bio-Rad Laboratories from $310.00 to $330.00 and gave the stock an "equal weight" rating in a research note on Wednesday, August 5th. Royal Bank Of Canada boosted their price target on shares of Bio-Rad Laboratories from $320.00 to $370.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 5th. Citigroup increased their price target on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. Finally, Weiss Ratings upgraded shares of Bio-Rad Laboratories from a "sell (d)" rating to a "hold (c-)" rating in a research report on Monday, August 17th. One investment analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, Bio-Rad Laboratories currently has an average rating of "Hold" and an average target price of $343.33.
Get Our Latest Report on Bio-Rad Laboratories
Bio-Rad Laboratories Stock Up 2.2%
Shares of Bio-Rad Laboratories stock opened at $390.10 on Wednesday. The company has a market cap of $10.43 billion, a P/E ratio of 47.28 and a beta of 1.06. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.33 and a current ratio of 3.14. Bio-Rad Laboratories has a one year low of $236.73 and a one year high of $390.83. The firm has a fifty day moving average of $319.88 and a two-hundred day moving average of $293.95.
Institutional Investors Weigh In On Bio-Rad Laboratories
Hedge funds and other institutional investors have recently bought and sold shares of the business. Hollencrest Capital Management acquired a new position in shares of Bio-Rad Laboratories during the 1st quarter worth $28,000. Danske Bank A S acquired a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at about $30,000. Geneos Wealth Management Inc. lifted its stake in shares of Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the period. Los Angeles Capital Management LLC purchased a new stake in Bio-Rad Laboratories during the fourth quarter worth about $47,000. Finally, Farther Finance Advisors LLC boosted its holdings in Bio-Rad Laboratories by 76.9% during the fourth quarter. Farther Finance Advisors LLC now owns 184 shares of the medical research company's stock worth $56,000 after buying an additional 80 shares in the last quarter. Institutional investors and hedge funds own 65.24% of the company's stock.
About Bio-Rad Laboratories
(
Get Free Report)
Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.
Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
